TEXAS CANCER GENETICS CONSORTIUM

我们提议成立德克萨斯州癌症遗传学联盟（TCGC），以响应癌症遗传学网络（CGN）RFA CA-97-004。 该TCGC将为CGN带来基础和临床癌症遗传学，人类和分子遗传学，机密人类癌症遗传学数据管理，人类遗传学社区外展，专业和公共教育以及癌症遗传咨询和测试影响的心理社会研究方面的广泛专业知识。 TCGC将包括现有的癌症高风险临床人群，德系犹太人人群，家族性乳腺癌，结肠癌，MEN 2，NF 1和其他遗传易感性综合征的登记，许多人在研究中随访了几十年，参与筛查和早期检测研究或化学预防试验的癌症高风险患者，以及一个大型的癌症患者数据库，从中识别高风险的家庭成员，以便潜在地招募到CGN。 德克萨斯州的人口在种族构成上是多样化的，TCGC包括在评估西班牙裔和非洲裔美国人社区在医疗保健方面的需求方面具有良好记录的调查人员，为这些社区及其医疗保健提供者提供健康教育，并招募他们参与家族性癌症登记和临床研究。 该申请的资助将为我们的TCGC提供机会，以加强我们在联盟内的互动，为CGN的设计和实施贡献我们的研究经验和专业知识，并利用我们的经验和专业知识招募高风险患者参与CGN方案。 长期目标是帮助确定癌症易感基因，其作用机制，频率，突变率和遗传或环境风险修饰因子，将这些信息整合到最佳的患者管理中，并评估需求和提供教育，以解决人类癌症遗传学的伦理和心理问题。

We propose a Texas Cancer Genetics Consortium (TCGC) in response to the Cancer Genetics Network (CGN) RFA CA-97-004. This TCGC would bring to the CGN extensive expertise in basic and clinical cancer genetics, human and molecular genetics, management of confidential human cancer genetics data, community outreach in human genetics, professional and public education, and psychosocial studies of the impact of cancer genetic counseling and testing. The TCGC will include existing cancer high risk clinical populations, Ashkenazi Jewish populations, registries of familial breast, colon, MEN2, NF1 and other genetic susceptibility syndromes, many followed in studies for decades, patients at high cancer risk participating in screening and early detection studies or chemoprevention trials, and a large database of cancer patients from which to identify high risk family members for potential recruitment to the CGN. The Texas population is diverse in ethnic makeup, and the TCGC includes investigators with proven track records in assessing needs of the Hispanic and African American communities in health care, in providing health education to those communities and their healthcare providers, and in recruiting their participation in familial cancer registries and clinical and research studies. Funding of this application would provide the opportunity for our TCGC to strengthen our within consortium interactions, to contribute our research experience and expertise to the CGN design and implementation, and to utilize our experience and expertise in recruitment of high risk patients to CGN protocols. The long term goal is to contribute to the identification of cancer susceptibility genes, their mechanisms of action, frequency, penetrance, and genetic or environmental risk modifiers, to integrate this information into optimal patient management, and to assess needs and provide education to address the ethical and psychosocial concerns surrounding human cancer genetics.